NewAmsterdam Pharma Company N.V.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $424.2M | $457.6M | $490.0M | $538.4M | $563.9M | $748.4M | $771.7M | $422.7M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $659.2M | $658.0M | $675.7M | $732.3M | $769.9M | $817.3M | $863.4M | $437.9M |
| Property, Plant & Equipment | $411.0K | $379.0K | $383.0K | $323.0K | $312.0K | $238.0K | $242.0K | $231.0K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $704.5M | $732.6M | $769.3M | $786.4M | $815.1M | $818.4M | $864.6M | $439.2M |
| Liabilities | ||||||||
| Accounts Payable | $5.4M | $8.1M | $9.0M | $3.6M | $5.9M | $6.1M | $4.7M | $7.0M |
| Total Current Liabilities | $73.0M | $67.4M | $85.8M | $58.3M | $36.5M | $40.9M | $106.9M | $41.3M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $73.0M | $67.4M | $85.9M | $58.4M | $36.6M | $41.1M | $107.1M | $60.3M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-875.0M | $-810.8M | $-762.4M | $-687.5M | $-615.5M | $-598.1M | $-558.6M | $-466.4M |
| Total Stockholders' Equity | $631.4M | $665.2M | $683.4M | $728.1M | $778.5M | $777.4M | $757.5M | $378.9M |